Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 3, 2011, Pages 248-252

  Sasaki, T ^a   Onishi, T ^a   Hoshina, A ^a  

^a ISE RED CROSS HOSPITAL   (Japan)

Author keywords

androgen deprivation therapy; bone metastasis; PSA; time to nadir

Indexed keywords

ALBUMIN; ANTIANDROGEN; BICARTAMIDE; CABAZITAXEL; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN AGONIST; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TREATMENT DURATION;

EID: 85027929998     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.14     Document Type: Article

References (22)

1. Eisenberger MA, Carducci M. Treatment of hormone-refractory prostate cancer. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Cambell-Walsh Urology, Vol 3, 9th edn Sounders: Philadelphia, PA, 2007, 3101-3117
2. De Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, De Pauw M, Members of the European Organization for Research on Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. J Urol 1989; 141: 883
3. Isikawa S, Soloway MS, Van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989; 141: 1139-1142 (Pubitemid 19124218)
4. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306-43136
5. Matzkin H, Soloway MS, Schellhammer PF, Chodac G, Smith JA, Caplan R et al. Prognostic factors in stage D2 prostate cancer treated with a pure non-steroidal antiandrogen. Cancer 1995; 72: 1055
6. Matzkin H, Eber E, Todd B, van der Zwaag R, Soloway MS. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostate cancer. Cancer 1992; 70: 2302-2309
7. Kwak C, Jeong SJ, Park NS, Lee E, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000
8. Sim HG, Lau WKO, Cheng CWS. Predictors of androgen independence in metastatic prostate cancer. BJU Int 2004; 93: 1221-1224 (Pubitemid 38823940)
9. Wilson DW, Harper ME, Jansen HM, Ikeda RM, Richards G, Peeling WB et al. A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation. Prostate 1985; 7: 131-141 (Pubitemid 16237916)
10. Soloway MS, HardemanSW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202 (Pubitemid 18023133)
11. Choueiri TK, XieW, dAmico AV, Ross RW, Hu JC, Pomerantz M et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115: 981-987
12. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone-refractory prostate cancer in the prostate specific antigen era. J Urol 2004; 171: 1525-1528 (Pubitemid 38365410)
13. Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen. Jap J Clin Oncol 2008; 38: 36-42 (Pubitemid 351248118)
14. Vollmer RT, Kantoff PW, Dawson NA, Vogelzang NJ. A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. Clin Cancer Res 1999; 5: 831-837 (Pubitemid 29180835)
15. Sylvester RJ, Denis L, de Voogt H, EORTC. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur Urol 1998; 33: 134-143 (Pubitemid 28073755)
16. Smaletz O, Scher H, Small EJ, Verbel DA, McMillan A, Regan K et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972-3982
17. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventos CX et al. Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer. Int J Biological Markers 2005; 20: 209-216 (Pubitemid 43103616)
18. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-016). J Clin Oncol 2006; 24: 3984-3990 (Pubitemid 46630748)
19. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2011; 137: 235-241
20. Arai Y, Yoshiki T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol 1990; 144: 1415-1419
21. Yeung F, Li X, Ellett J, Trapman J, Kao C, Chung LM. Regions of prostate-specific antigen (PSA) promoter confer androgenindependent expression of PSA in prostate cancer cells. J Biol Chem 2000; 275: 40846-40855 (Pubitemid 32054905)
22. Onishi T, Yamakawa K, Franco OE, Kawamura J, Watanabe M, Shiraishi T et al. Mitogen-activated protein kinase pathway is involved in alpha 6 integrin gene expression in androgenindependent prostate cancer cell: role of proximal Sp1 consensus sequence. Biochemica Biophysica Acta 2001; 14728: 1-10